ルテチウムオキソドトレオチド (177Lu)
Gut 61 (1): 6–32. (January 2012). doi:10.1136/gutjnl-2011-300831. PMC 3280861. PMID 22052063. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280861/.
1 2 “The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours”. European Journal of Nuclear Medicine and Molecular Imaging 40 (5): 800–16. (May 2013). doi:10.1007/s00259-012-2330-6. PMC 3622744. PMID 23389427. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622744/.
↑ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). 2019. {{cite report}}: 不明な引数|month=は無視されます。 (説明)
1 2 “ルタテラ静注 添付文書”. www.info.pmda.go.jp. 2021年10月17日閲覧。